Citations

Showing 10 of 108119 citations.

Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study
Nounu, Aayah , Richmond, Rebecca C. , Stewart, Isobel D., Surendran, Praveen , Wareham, Nicholas J. , Butterworth, Adam S. , Weinstein, Stephanie J. , Figueiredo, Jane C. , Lindor, Noralane M. , Casey, Graham , Marchand, Loı̈c Le , Ulrich, Cornelia M. , Li, Christopher, Dujinhoven, Fränzel van, Gsur, Andrea , Moreno, Vı́ctor , Vodička, Pavel , Vodičková, Ludmila, Alwers, Elizabeth , Chang‐Claude, Jenny , Sakoda, Lori C. , Slattery, Martha L. , Schoen, Robert , Gunter, Marc J. , Castellvı́-Bel, Sergi , Kim, Hyeong Rok , Li, Li , Bishop, D. Timothy , Buchanan, Daniel D. , Gruber, Stephen B. , Rennert, Gad , Harrison, Tabitha A. , Woods, Michael O. , Schafmayer, Clemens , Guelpen, Bethany Van , Gallinger, Steven , Berndt, Sonja I. , Lindblom, Annika , Wu, Anna H. , Peters, Ulrike , Scherer, Dominique , Bermejo, Justo Lorenzo , Brenner, Hermann , Hoffmeister, Michael , Relton, Caroline L. , Drew, David A. , Figueiredo, Jane C , Marchand, Loïc Le , Ulrich, Cornelia M , Gsur, Andrea , Moreno, Victor , Sakoda, Lori C , Castellví-Bel, Sergi , Buchanan, Daniel D , Lorenzo-Bermejo, Justo , Hoffmeister, Michael , Rennert, Gad , Gunter, Marc J , Drew, David A , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Bishop, D Timothy , Vodicka, Pavel , Lindblom, Annika , Albanes, Demetrius , Baron, John A. , Hopper, John L. , Newcomb, Polly A. , Platz, Elizabeth A. , Campbell, Peter T. , Amitay, Efrat L. , Schoen, Robert, Kweon, Sun-Seog , Chan, Andrew T. , Zheng, Wei , Giles, Graham G. , Stadler, Zsofia , Lin, Yi , Keku, Temitope O , Hampel, Heather , Pharoah, Paul D.P. , Wolk, Alicja , White, Emily , Williams, Ann Caroline

Mayo Clinic

Nutrients | November 21, 2021 | Volume: 13 | Issue: 11 | Pages: 4164

10.3390/nu13114164 | PMID 34836419 Get It

Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. Aspirin (acetylsalicylic acid, that rapidly deacetylates to SA) is an effective primary and secondary chemopreventive agent. Through a Mendelian randomization (MR) approach, we aimed to address whether levels of SA affected CRC risk, stratifying by aspirin use. A two-sample MR analysis was performed using GWAS summary statistics of SA (INTERVAL and EPIC-Norfolk, N = 14,149) and CRC (CCFR, CORECT, GECCO and UK Biobank, 55,168 cases and 65,160 controls). The DACHS study (4410 cases and 3441 controls) was used for replication and stratification of aspirin-use. SNPs proxying SA were selected via three methods: (1) functional SNPs that influence the activity of aspirin-metabolising enzymes; (2) pathway SNPs present in enzymes’ coding regions; and (3) genome-wide significant SNPs. We found no association between functional SNPs and SA levels. The pathway and genome-wide SNPs showed no association between SA and CRC risk (OR: 1.03, 95% CI: 0.84–1.27 and OR: 1.08, 95% CI: 0.86–1.34, respectively). Results remained unchanged upon aspirin use stratification. We found little evidence to suggest that an SD increase in genetically predicted SA protects against CRC risk in the general population and upon stratification by aspirin use.
Retinoid Agonists in the Targeting of Heterotopic Ossification
Pignolo, Robert J. , Pacifici, Maurizio

Mayo Clinic

Cells | November 21, 2021 | Volume: 10 | Issue: 11 | Pages: 3245

10.3390/cells10113245 | PMID 34831466 Get It

Retinoids are metabolic derivatives of vitamin A and regulate the function of many tissues and organs both prenatally and postnatally. Active retinoids, such as all trans-retinoic acid, are produced in the cytoplasm and then interact with nuclear retinoic acid receptors (RARs) to up-regulate the transcription of target genes. The RARs can also interact with target gene response elements in the absence of retinoids and exert a transcriptional repression function. Studies from several labs, including ours, showed that chondrogenic cell differentiation and cartilage maturation require (i) the absence of retinoid signaling and (ii) the repression function by unliganded RARs. These and related insights led to the proposition that synthetic retinoid agonists could thus represent pharmacological agents to inhibit heterotopic ossification (HO), a process that recapitulates developmental skeletogenesis and involves chondrogenesis, cartilage maturation, and endochondral ossification. One form of HO is acquired and is caused by injury, and another severe and often fatal form of it is genetic and occurs in patients with fibrodysplasia ossificans progressiva (FOP). Mouse models of FOP bearing mutant ACVR1R206H, characteristic of most FOP patients, were used to test the ability of the retinoid agonists selective for RARα and RARγ against spontaneous and injury-induced HO. The RARγ agonists were found to be most effective, and one such compound, palovarotene, was selected for testing in FOP patients. The safety and effectiveness data from recent and ongoing phase II and phase III clinical trials support the notion that palovarotene may represent a disease-modifying treatment for patients with FOP. The post hoc analyses showed substantial efficacy but also revealed side effects and complications, including premature growth plate closure in some patients. Skeletally immature patients will need to be carefully weighed in any future regulatory indications of palovarotene as an important therapeutic option in FOP.
Targeting ineffective hematopoiesis in myelodysplastic syndromes
Patnaik, Mrinal M. , Santini, Valeria

Mayo Clinic

American Journal of Hematology | November 20, 2021 | Volume: 97 | Issue: 2 | Pages: 171-173

10.1002/ajh.26416 | PMID 34800318 Get It

Sensitivity analysis in classification using Bayesian smoothing spline ANOVA probit regression
Zhang, Chunzhe, Storlie, Curtis B. , Lee, Thomas C. M.

Mayo Clinic

Canadian Journal of Statistics | November 20, 2021 | Volume: 50 | Issue: 3 | Pages: 928-950

10.1002/cjs.11669 Get It

For many classification problems, in addition to providing accurate classification results, very often it is equally important to determine which predictors are contributing to the results, and by how much. This motivates this article, where a new sensitivity analysis framework is developed for classification problems to address this issue. The effectiveness of this framework is illustrated through simulation studies and application to real data. Notice that this framework can be coupled with different classification methods. However, in practice it is recommended to pair it with a classification method called Bayesian smoothing spline ANOVA probit regression (BSSANOVA). When compared with other existing methods through numerical experiments, BSSANOVA performs extremely well for both classification and sensitivity analysis.
Mimics of Erdheim–Chester disease
Abeykoon, Jithma P. , Ravindran, Aishwarya , Shah, Meera , Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Shah, Mithun V , Goyal, Guarav , Vassallo, Robert , Ravindran, Aishwarya , Ryu, Jay H , Rech, Karen L. , Young, Jason R. , Tobin, W. Oliver , Bennani, N. Nora , Koster, Matthew J. , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

British Journal of Haematology | November 20, 2021 | Volume: 196 | Issue: 4 | Pages: 984-994

10.1111/bjh.17949 | PMID 34799853 Get It

SummaryErdheim–Chester disease (ECD) is a rare histiocytic neoplasm with frequent multiorgan involvement. An accurate diagnosis of ECD requires the correlation of clinical features, histopathologic and radiologic findings. We describe a case series of patients with a referral diagnosis of ECD, whereby the diagnosis was changed to non‐histiocytic diseases after comprehensive review at a tertiary care center. This accurate revision of the referral diagnosis of ECD enabled initiation of proper disease‐directed therapy in a timely manner for these patients and avoided unnecessary exposure to systemic cytotoxic chemotherapy or targeted agents. Our study highlights the value of a multidisciplinary team of histiocytosis experts in confirming the diagnosis of ECD and also brings attention to other conditions to consider that can mimic ECD, including osteopoikilosis, tenosynovial giant cell tumour, IgG4‐related disease, fibrous dysplasia and chronic recurrent multifocal osteomyelitis.
Involvement of MAP3K7 in FMD2 and CSCF, delineation of genotype/phenotype correlations.
Senden, Richelle, Konink, Charlotte de , Trezza, Rossella Avagliano , Bassetti, Jennifer A. , Bever, Yolande van , Brooks, Alice S. , Guan, Qiaoning , Klee, Eric W. , Shikany, Amy , Terhal, Paulien A., Wessels, Marja W., Wieringen, Hester van, Gooch, Catherine , Niceta, Marcello , Demirdas, Serwet , Woerden, Geeske M. van , Baban, Anwar , Bird, Lynne M. , Bon, Bregje W.M. van , Marcelis, Carlo , Morales‐Rosado, Joel A. , Schimmenti, Lisa A. , Weaver, Kathryn , Hurst, Anna , Tartaglia, Marco , Elgersma, Ype

Mayo Clinic

No container title available | November 20, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163741470.06165246/v1 Get It

Mitogen-Activated Protein 3 Kinase 7 (MAP3K7, MIM 602614) encodes the ubiquitously expressed transforming growth factor β (TGF-β)–activated kinase 1 (TAK1), which plays a crucial role in many cellular processes. Variants in the MAP3K7 gene have been linked to 2 distinct disorders: frontometaphyseal dysplasia type 2 (FMD2, MIM #617137) and cardiospondylocarpofacial syndrome (CSCF, MIM #157800). The fact that different variants can induce 2 distinct phenotypes suggests a phenotype/genotype correlation, but no side-by-side comparison has been done thus far to confirm this. Here we significantly expand the cohort and the description of clinical phenotypes for individuals with CSCF and FMD2 who carry variants in MAP3K7. We show that in contrast to FMD2-causing variants, CSCF-causing variants in MAP3K7 have a loss-of-function effect. Additionally, patients with pathogenic variants in MAP3K7 are at risk for cardiac disease, have symptoms associated with connective tissue disease and we show overlap in clinical phenotypes of CSCF with Noonan syndrome. Together, we provide evidence for a molecular fingerprint of FMD2- versus CSCF-causing MAP3K7 variants and conclude that variants in MAP3K7 should be considered in the differential diagnosis of patients with syndromic congenital cardiac defects and/or cardiomyopathy, syndromic connective tissue disorders and in the differential diagnosis of Noonan syndrome.
Bizarre Chorionic-type Trophoblast in Second-trimester and Third-trimester Placentas
Murdock, Tricia A, Varghese, Aaron , Xing, Deyin , Schoolmeester, John K., Alexander, Caitlin, Baergen, Rebecca N., Dahoud, Wissam , Hopkins, Mark R, Askin, Frederic B. , Vang, Russell , Schoolmeester, J. Kenneth , Murdock, Tricia A, Hopkins, Mark R

Mayo Clinic

American Journal of Surgical Pathology | November 20, 2021 | Volume: 46 | Issue: 2 | Pages: 258-267

10.1097/pas.0000000000001838 | PMID 34799484 Get It

Bizarre (atypical/symplastic) cells have been described in various gynecologic normal tissues and benign neoplasms. This type of bizarre cytologic change is usually an incidental finding and is regarded as a benign process. We describe 17 cases of bizarre chorionic-type trophoblast in second-trimester and third-trimester placentas that created concern for an underlying/undersampled or incipient intraplacental trophoblastic neoplasm, predominantly found in intervillous trophoblastic islands (11/17), placental septae (6/17), chorionic plate (1/17), and/or the chorion layer of fetal membranes (2/17). The bizarre trophoblastic cells exhibited sheet-like or nested architecture, had a multifocal/patchy distribution, and/or were present as individual cells within hyaline stroma; they were characterized by large nuclei with smudgy chromatin and occasional intranuclear pseudoinclusions. The degree of atypia was classified as mild (0/17), moderate (3/17), or severe (14/17). Mitotic figures and necrosis were not identified. A dual immunohistochemical stain for trophoblast (hydroxyl-delta-5-steroid dehydrogenase) and a proliferation marker (Ki-67), performed in 15 cases, demonstrated 0% to very low proliferative activity within the bizarre trophoblast (0% to 2% [10/15], 3% to 8% [5/15]). Immunohistochemical stains for fumarate hydratase showed intact/retained expression in the bizarre cells in 7 of 7 cases. Clinical follow-up ranged from 1 to 45 months, and all patients were alive and well without subsequent evidence of a gestational trophoblastic or other neoplasms. We conclude that bizarre chorionic-type trophoblast in second-trimester or third-trimester placentas have the potential to mimic an intraplacental trophoblastic neoplasm but are likely a benign degenerative change. This study expands the spectrum of bizarre cells that occur in the gynecologic tract.
Filling in the Spaces in Cardiovascular Epidemiology
Paneth, Nigel, Joyner, Michael J., Casadevall, Arturo, Joyner, Michael J. , Joyner, Michael J , Paneth, Nigel, Casadevall, Arturo

Mayo Clinic

Epidemiology | November 20, 2021 | Volume: 33 | Issue: 1 | Pages: 34-36

10.1097/ede.0000000000001435 | PMID 34799481 Get It

Tracheobronchoplasty and Diaphragmatic Plication under VV ECMO for Combined ECAC and Diaphragmatic Paralysis
Tatari, Mehmet M. , Thomas, Mathew , Patel, Neal M. , Fernández-Bussy, Sebastián , Hazelett, Britney N. , Johnson, Margaret M. , Abia‐Trujillo, David

Mayo Clinic

Case Reports in Pulmonology | November 19, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-4

10.1155/2021/5565754 | PMID 34840846 Get It

The coexistence of expiratory central airway collapse and diaphragmatic paralysis presents a diagnostic and treatment challenge. Both entities are underrecognized causes of dyspnea, cough, sputum production, and orthopnea. Optimal treatment must be individualized and is best achieved by a multidisciplinary team. We present a case of a patient with profound functional impairment from dyspnea and hypoxemia due to expiratory central airway collapse, complicated by bronchiectasis from recurrent respiratory infections, and diaphragmatic paralysis.